PDCD1 and non-small cell lung carcinoma: It is found that the PD-1 inhibitors (e.g., Nivolumab, Cimipritimab and Bolizumab) and the PD-L1 inhibitors (e.g., Durvalumab and Atezolizumab) have benefited OS in clinical trials of NSCLC treatments.